References in periodicals archive ?
o IL-1?, IL-1?, IL-2, IL-3, IL-4, IL-6, IL-10, IL-12p70, IL-17, MCP-1, TNF-?, MIP-1?, GMCSF, RANTES
No association was observed between serum anti-IL-2 IgG and the other parameters, which included age, disease duration, white blood cells, hemoglobin, platelets, complements, anti-dsDNA antibodies, AnuA, 24 h proteinuria excretion, and serum IL-2 (data not shown).
IL-15 activates a number of intracellular signaling molecules, including the janus kinase and members of the transcription factor family of signal transducers and activators of transcription.8 Due to sharing of receptor subunits between IL-2 and IL-15, both of these cytokines have similar downstream effects in T cells, including the induction of bci-2, the activation of the MAP Kinase pathway, and the phosphorylation of ick and syk kinases.10
Values Small Van Krevelen Hoy -[CH.sub.3] 438 420 303.4 -COO- 634 512 668 [FORMULA NOT REPRODUCIBLE IN ASCII] 57 140 176 The solubility parameter of IL-2 was calculated using a molar volume of 651 [cm.sup.3]/mol by the same group contribution technique.
In both trials, people taking IL-2 with antiretrovirals rapidly gained more CD4 cells than people taking only antiretrovirals, although the antiretroviral-only groups steadily gained CD4 cells throughout the study.
In general, increased numbers of IL-2, IL-10 or IL-2R positive cells were found in tissues from patients with CIN when compared to adjacent normal tissues and normal controls.
Possible reasons for the positive findings observed by Dybul and colleagues, (24) include different HAART study regimens, shorter treatment interruption, absence of drug-resistance mutations prior to study enrollment, higher CD4 T cell nadir, and history of IL-2 treatment in the majority of patients (patients in other comparable studies had no history of IL-2).
The levels of IFN-[gamma], IL-2, and IL-6 in the culture supernatants were determined using the commercially developed enzyme-linked immunosorbent assays (ELISA) (BioSource International, Inc., Camarillo, CA) and a spectrophotometric microplate reader (SpectraMax 250; Molecular Devices Co., Sunnyvale, CA).
Compared with either drug alone, IL-2 and M40403 together were better at reducing the spread of cancer in mice.
In addition, the FDA reiterated the need to demonstrate a significant benefit of Ceplene/IL-2 vs IL-2 monotherapy on overall survival, which needs to be the primary endpoint of the trial.
By the early 1990s, it was clear that IL-2, when used intermittently and in conjunction with anti-HIV therapy, had the most pronounced impact on increasing CD4 T cell counts of any therapy ever studied for the treatment of HIV disease.